PRECISION BIOSCIENCES INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M |
| Research and development | $54.2M | $59.6M | $53.4M | $46.1M | $115.2M |
| Operating expenses | $86.4M | $94.9M | $92.5M | $87.4M | $154.9M |
| Operating income | -$52.1M | -$26.2M | -$43.7M | -$62.3M | -$39.4M |
| Interest expense | $1.4M | $1.8M | $2.2M | $1.1M | $132,000 |
| Pretax income | -$45.7M | $7.2M | — | — | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$45.7M | $7.2M | -$61.3M | -$111.6M | -$30.6M |
| Balance Sheet | |||||
| Cash and equivalents | $110.8M | $85.9M | $116.7M | $189.6M | $143.7M |
| Current assets | $118.7M | $95.0M | $136.4M | $199.1M | $161.8M |
| Total assets | $154.4M | $136.4M | $159.8M | $238.2M | $211.5M |
| Current liabilities | $8.9M | $15.0M | $50.0M | $59.7M | $36.0M |
| Total liabilities | $62.2M | $80.0M | $140.9M | $177.7M | $120.3M |
| Stockholders' equity | $92.2M | $56.4M | $18.9M | $60.4M | $91.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$65.8M | -$58.4M | -$84.1M | -$45.8M | -$10.9M |
| Depreciation and amortization | $1.5M | $3.4M | $6.8M | $7.8M | $9.0M |
| Stock-based compensation | $10.2M | $12.6M | $14.0M | $19.2M | $16.5M |
| Capital expenditure | $85,000 | $250,000 | $2.0M | $3.3M | $5.1M |
| Free cash flow | -$65.9M | -$58.7M | -$86.1M | -$49.1M | -$15.9M |
| Impairments | $36,000 | $0 | $0 | $10.8M | — |
Shares outstanding 25.8M · Free float 39.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.